Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

9.331 -0.763 (-7.56%)
Streaming Delayed Price Updated: 10:55 AM EDT, Aug 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,302
Open 9.420
Bid (Size) 9.250 (11)
Ask (Size) 9.430 (5)
Prev. Close 10.09
Today's Range 9.202 - 9.500
52wk Range 2.760 - 10.59
Shares Outstanding 34,432,122
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
SelectQuote Posts Better-Than-Expected Results, Joins Nutex Health, NIO, MINISO Group And Other Big Stocks Moving Higher On Thursday
 
Via Benzinga
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
From Nanobiotix S.A.
Via GlobeNewswire

Performance

YTD
+221.8%
+221.8%
1 Month
+37.0%
+37.0%
3 Month
+144.9%
+144.9%
6 Month
+141.1%
+141.1%
1 Year
+76.4%
+76.4%

More News

Read More
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
Earnings Scheduled For April 2, 2025
Via Benzinga
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
From Nanobiotix S.A.
Via GlobeNewswire
Cancer-Focused Nanobiotix Adjusts $2.7 Billion Johnson & Johnson Agreement To Strengthen Finances And Relieve Funding Burden
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire

Frequently Asked Questions

Is Nanobiotix S.A. - ADSs publicly traded?
Yes, Nanobiotix S.A. - ADSs is publicly traded.
What exchange does Nanobiotix S.A. - ADSs trade on?
Nanobiotix S.A. - ADSs trades on the Nasdaq Stock Market
What is the ticker symbol for Nanobiotix S.A. - ADSs?
The ticker symbol for Nanobiotix S.A. - ADSs is NBTX on the Nasdaq Stock Market
What is the current price of Nanobiotix S.A. - ADSs?
The current price of Nanobiotix S.A. - ADSs is 9.331
When was Nanobiotix S.A. - ADSs last traded?
The last trade of Nanobiotix S.A. - ADSs was at 08/25/25 10:55 AM ET
What is the market capitalization of Nanobiotix S.A. - ADSs?
The market capitalization of Nanobiotix S.A. - ADSs is 321.30M
How many shares of Nanobiotix S.A. - ADSs are outstanding?
Nanobiotix S.A. - ADSs has 321M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback